

- 1 -

SEQUENCE LISTING

<110> Bayer AG, BHC

<120> Diagnostics and Therapeutics for Diseases Associated with Kallikrein 8 (KLK8)

<130> Le A 36 870

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 783

<212> DNA

<213> Homo sapiens

<400> 1

```

atgggacgcc cccgacctcg tgcggccaag acgtggatgt tcctgctctt gctgggggga      60
gcctgggcag gacactccag ggcacaggag gacaagggtgc tgggggggtca tgagtgccaa      120
ccccattcgc agccttggtc ggccggccttg ttccagggcc agcaactact ctgtggcggg      180
gtccttgtag gtggcaactg ggtccttaca gctgcccact gtaaaaaacc gaaatacaca      240
gtacgcctgg gagaccacag cctacagaat aaagatggcc cagagcaaga aatacctgtg      300
gttcagtcca tcccacaccc ctgctacaac agcagcgatg tggaggacca caaccatgat      360
ctgatgcttc ttcaactgcg tgaccaggca tccttggggg ccaaagttaa gcccatcagc      420
ctggcagatc attgcaccca gcctggccag aagtgcaccg tctcaggctg gggcactgtc      480
accagtcccc gagagaattt tcctgacact ctcaactgtg cagaagtaaa aatctttccc      540
cagaagaagt gtgaggatgc ttaccggggg cagatcacag atggcatggt ctgtgcaggc      600
agcagcaaag gggctgacac gtgccagggc gattctggag gcccctggt gtgtgatggt      660
gcactccagg gcatcacatc ctggggctca gaccctgtg ggaggtccga caaacctggc      720
gtctatacca acatctgccg ctacctggac tggatcaaga agatcatagg cagcaagggc      780
tga                                                                                          783

```

<210> 2

<211> 260

<212> PRT

<213> Homo sapiens

<400> 2

```

Met Gly Arg Pro Arg Pro Arg Ala Ala Lys Thr Trp Met Phe Leu Leu
1      5      10
Leu Leu Gly Gly Ala Trp Ala Gly His Ser Arg Ala Gln Glu Asp Lys
20     25     30
Val Leu Gly Gly His Glu Cys Gln Pro His Ser Gln Pro Trp Gln Ala
35     40     45
Ala Leu Phe Gln Gly Gln Gln Leu Leu Cys Gly Gly Val Leu Val Gly
50     55     60
Gly Asn Trp Val Leu Thr Ala Ala His Cys Lys Lys Pro Lys Tyr Thr
65     70     75     80
Val Arg Leu Gly Asp His Ser Leu Gln Asn Lys Asp Gly Pro Glu Gln
85     90     95
Glu Ile Pro Val Val Gln Ser Ile Pro His Pro Cys Tyr Asn Ser Ser
100    105    110
Asp Val Glu Asp His Asn His Asp Leu Met Leu Leu Gln Leu Arg Asp
115    120    125
Gln Ala Ser Leu Gly Ser Lys Val Lys Pro Ile Ser Leu Ala Asp His
130    135    140
Cys Thr Gln Pro Gly Gln Lys Cys Thr Val Ser Gly Trp Gly Thr Val
145    150    155    160
Thr Ser Pro Arg Glu Asn Phe Pro Asp Thr Leu Asn Cys Ala Glu Val
165    170    175
Lys Ile Phe Pro Gln Lys Lys Cys Glu Asp Ala Tyr Pro Gly Gln Ile
180    185    190

```

- 2 -

Thr Asp Gly Met Val Cys Ala Gly Ser Ser Lys Gly Ala Asp Thr Cys
 195 200 205
 Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Asp Gly Ala Leu Gln Gly
 210 215 220
 Ile Thr Ser Trp Gly Ser Asp Pro Cys Gly Arg Ser Asp Lys Pro Gly
 225 230 235 240
 Val Tyr Thr Asn Ile Cys Arg Tyr Leu Asp Trp Ile Lys Lys Ile Ile
 245 250 255
 Gly Ser Lys Gly
 260

<210> 3
 <211> 21
 <212> DNA
 <213> artificial sequence

<220>
 <223> forward primer

<400> 3
 cctggcgtct ataccaacat c 21

<210> 4
 <211> 19
 <212> DNA
 <213> artificial sequence

<220>
 <223> reverse primer

<400> 4
 atcagccctt gctgcctat 19

<210> 5
 <211> 27
 <212> DNA
 <213> artificial sequence

<220>
 <223> probe

<400> 5
 cgctacctgg actggatcaa gaagatc 27